Safety, tolerability, and pharmacokinetics of AZD5462, a small molecule agonist of the RXFP1 relaxin receptor

Back

ESC Professional Premium Access

Safety, tolerability, and pharmacokinetics of AZD5462, a small molecule agonist of the RXFP1 relaxin receptor

Session: Experimental therapies for heart failure

Topic: Pharmacotherapy

Speaker: Doctor J. Rosenmeier (Gothenburg, SE)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Doctor Jaya Birgitte Rosenmeier

AstraZeneca, Gothenburg (Sweden)

1 follower

5 more presentations in this session

The acute hemodynamic effects of sodium lactate infusion: increased cardiac output and decreased afterload in a randomized trial in pigs

Speaker: Mr O. Horsdal (Aarhus, DK)

Non-steroidal mineralocorticoid receptor antagonist, finerenone, attenuates obesity- and hypertension-induced cardiomyocyte hypertrophy in a blood pressure-independent manner.

Speaker: Doctor K. Morikawa (Kumamoto, JP)

Therapeutic potential of pharmacological inhibition of programmed apoptosis, necroptosis, and ferroptosis in improving left ventricular function in post-myocardial infarction rats

Speaker: Doctor C. Piamsiri (Chiang Mai, TH)

Effects of vericiguat on redox signaling in cardiomyocyte

Speaker: Doctor T. Harada (Yufu City, JP)

Long-acting CRF2 peptide agonist improves cardiac function in a rat heart failure model

Speaker: Mr Y. Stephan (Rouen, FR)

Access the full session

Experimental therapies for heart failure

Speakers: Doctor J. Rosenmeier, Mr O. Horsdal, Doctor K. Morikawa, Doctor C. Piamsiri, Doctor T. Harada...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources